Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course

Milena Anatchkova,¹ Anne Brooks,¹ Laura Swett,¹ Ann Hartry,² Ruth A. Duffy,³ Ross A. Baker,³ Lene Hammer-Helmich,⁴ and Myrlene Sanon Aigbogun⁵

¹Patient Centered Research, Evidera, Bethesda, MD, USA

²Health Economics and Outcomes Research, Lundbeck LLC, Deerfield, IL, USA

³Medical Affairs, Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA

⁴Real World Evidence and Epidemiology, H. Lundbeck A/S, Valby, Denmark

⁵Health Economics and Outcomes Research, Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA

ABSTRACT

Objectives: More than 90% of individuals with Alzheimer's disease (AD) experience behavioral and neuropsychiatric symptoms (NPS), such as agitation. However, little is known regarding the specific burden of agitation for Alzheimer's patients.

Design: A global systematic literature review was conducted in MEDLINE and Embase for studies of clinical, humanistic, and economic burden of agitation in AD/dementia published from 2006–2016. References of identified papers and related literature reviews were examined. Studies meeting predetermined inclusion criteria for burden of agitation/NPS were summarized.

Results: Eighty papers met the inclusion criteria for burden of agitation in dementia. Wide ranges of agitation prevalence were reported, but few papers provided information on incidence. The association of agitation with AD severity was presented in multiple studies; a few suggested positive association of agitation with mortality.

Conclusions: High prevalence of agitation is consistent with earlier reports, but several gaps in understanding of agitation in AD need further exploration.

Key words: agitation, Alzheimer's disease, systematic review, agitation burden

Introduction

Alzheimer's disease (AD) is the most common cause of dementia among older adults; it accounts for an estimated 60–80% of cases (Alzheimer's Association, 2015). In addition to loss of memory and cognition, more than 90% of individuals with AD experience behavioral and neuropsychiatric symptoms (NPS), such as agitation, aggression, depression, hallucinations, and delusions, over the course of their illness (Alzheimer's Society, 2011; Steinberg *et al.*, 2008). NPS, also referred to as behavioral and psychological symptoms of dementia, are associated with increased morbidity, mortality, healthcare use, earlier nursing home placement, and caregiver burden and distress (Porsteinsson *et al.*, 2014). While agitation is common among neuropsychiatric disorders, there was no consensus definition for it until recently—non-specific lay definitions were used (Cummings *et al.*, 2015), making it difficult to compare studies and summarize existing evidence on the burden of agitation. Because of the lack of an accepted definition or assessment tool for agitation, there is a gap in the understanding of the burden of AD specific to agitation. A systematic review of the burden of agitation and NPS can help address this gap in knowledge.

The goal of this systematic literature review (SLR) was to map the existing evidence to better understand the total clinical, humanistic, and economic burden associated with agitation in adult patients with AD. The specific objective of this paper is to describe the results regarding agitation incidence and prevalence, and its association with disease progression and mortality, in adult patients with AD based on results from the broader SLR.

Correspondence should be addressed to: Myrlene Sanon Aigbogun, MPH, Health Economics and Outcomes Research, Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center, Princeton, NJ 08540, USA. Phone: +1.609.512.4456; Fax: +1.609.249.7342. Email: Myrlene.Sanon@ otsuka-us.com. Received 27 Mar 2018; revision requested 24 Jul 2018; revised version received 06 Sep 2018; accepted 29 Sep 2018. First published online 11 March 2019.

CRITERIA	INCLUSION	EXCLUSION			
Population	Alzheimer's disease, dementia with agitation	Other pathology, pediatric population, non-human studies, in-vitro studies			
Intervention	No limitations based on intervention				
Comparator	No limitation based on comparator				
Outcomes	Agitation incidence, prevalence, mortality associated with agitation, natural history and agitation, disease severity	All others			
Study design	Population observational studies (e.g., cross-sectional, prospective cohort, retrospective cohort), sample size >50	Case study, study protocols, qualitative studies, methodological studies, studies with sample size <50. Literature reviews retained for review of references, but not summarized.			
Language	English	Non-English			
Time period	2006–2016	Pre-2006			

Table 1. PICOS criteria for burden of agitation in AD

Abbreviations: AD = Alzheimer's disease; PICOS = population, intervention, comparator, outcomes, study design.

Patients and methods

A systematic literature search, based on a preapproved Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) protocol and consistent with the PRISMA statement, was conducted for studies published between 2006 and 2016. The search was conducted in MEDLINE (via PubMed) and Embase. In addition, conference proceedings (including websites, posters, and meeting abstracts) from the two most recent meetings (last two years or last two major meetings) were searched for five professional organizations (Alzheimer's Association-International Conference on Alzheimer's Disease; International Psychogeriatric Association [IPA]; Alzheimer's Disease International [ADI]; American Association for Geriatric Psychiatry [AAGP]; International Society of Pharmacoeconomics and Outcomes Research [ISPOR]).

Blocks of medical subject heading (MeSH) terms were used to identify the most relevant articles, research papers, and conference papers that described the clinical burden associated with agitation in AD. Agitation terms were based on the consensus definition of agitation issued by the IPA (Cummings et al., 2015), which includes behaviors that indicate severe emotional distress (e.g., irritability, rapid changes in mood), excessive motor activity (e.g., pacing, rocking, restlessness), physical aggression (e.g., pushing, hitting, kicking), and verbal aggression (e.g., shouting, cursing, yelling)-these behaviors must not be solely attributable to another psychiatric disorder (e.g., depression, psychosis). The focus of this review was specifically on agitation; however, studies that did not explicitly use the term agitation but reported on the behaviors noted above were included. Unless specifically stated otherwise, results are presented as a combination of agitation and related NPS in this report.

The search strategy used is presented in Table S1 and Table S2 of the Supplementary Search Strategy Tables file and full list of references in presented in Supplementary Appendix, published as supplementary material online attached to the electronic version of this paper. SLRs were included in the initial search to review the reference list; this was to ensure all additional, relevant papers were included in the review.

All abstracts were reviewed using DistillerSR[®], a literature review extraction software, which assists with the organization, extraction, and categorization of the literature. Screening was performed by three trained reviewers at two levels. At Level 1, titles and abstracts of identified records were screened for exclusion criteria (Table 1). Thirty percent of the excluded abstracts were screened by a second, independent reviewer to ensure agreement. At Level 2, full-text articles were screened, and those meeting the eligibility criteria were tabled. The inclusion of all papers into the review was confirmed by a second reviewer. Data abstraction was completed in table format as reported. Qualitative synthesis of the information was conducted. No quantitative summaries were planned.

Results

The database search yielded 1,415 references, of which 1,407 remained after duplicates were removed. All 1,407 records were screened based on the protocol-defined criteria—365 were accepted for full-text screening. Of these, 206 papers were included in the final qualitative review of AD agitation burden (Figure 1). Of the 206 studies included in the final qualitative review, those providing information on burden of agitation were summarized by




Figure 1. PRISMA flow diagram: SLR burden of illness associated with agitation in Alzheimer's disease.

protocol-defined groups. This paper summarizes findings related to incidence (4 papers), prevalence (55 papers), natural progression of agitation symptoms (17 papers), association of agitation and disease severity (34 papers and three conference abstracts), and association of agitation and mortality (5 studies). Publications related to humanistic, caregiver, and economic burden were also reviewed, but results are not reported in this paper (Anatchkova *et al.*, 2017).

Incidence of agitation/behavioral symptoms in AD

Four studies evaluating the incidence of agitation/ behavioral symptoms in AD were identified; three from Norway and one from The Netherlands (Table 2). Incidence was defined in three studies as the proportion of participants who had no NPS at one timepoint but developed them at a later timepoint in the study. Cumulative incidence was defined as the proportion of patients who had no agitation/NPS at baseline, but developed these during the study. Of the three studies conducted in Norway, one identified the cumulative incidence of clinically significant agitation over a 2-year period to be 24.3% (Bergh *et al.*, 2011), the 12-month cohort study found the incidence rate to be 18.8% (Selbaek *et al.*, 2008), and the 4-year longitudinal study indicated a cumulative incidence rate of 36% (Selbaek *et al.*, 2014). The Netherlands study, which was longitudinal, assessed 2-year incidence of agitation, which ranged from 10.9% to 18.2% (Wetzels *et al.*, 2010b). All studies used a population sample of nursing home (NH) residents. Studies of incidence of agitation/behavioral symptoms in AD were only published in European countries; no studies of incidence were published in the North American, South American, or Asian regions. In addition, all studies presented findings for patients in nursing homes, while information on incidence of agitation for patients residing at home or seen as outpatients was lacking.

Prevalence of agitation/behavioral symptoms in AD

Fifty-five studies reported the prevalence of agitation and or behavioral symptoms in AD (Table 3). Study types included cross-sectional (n=31), longitudinal or retrospective longitudinal (n=23), and before/after study/interrupted time series (n=1).

The overall prevalence of agitation ranged from 5% to 88% across all studies (Figure 2), with 21 (38%) showing a prevalence of agitation \geq 50%.

Table 2. Incidence of agitation in AD

CITATION	COUNTRY	TYPE OF STUDY	TIME PERIOD	SAMPLE SIZE	age (years ±)	STUDY Population	SETTING	INCIDENCE
Bergh <i>et al.</i> (2011)	Norway	Cross-sectional	2008–2010	169	84.9 (6.7)	Dementia	NH	Cumulative Incidence Rate 24.2% Agitation 42.6% Irritability 82.9% at least one NPS
Selbaek <i>et al.</i> (2014)	Norway	Longitudinal Cohort	2004–2008	931	84.5 (7.5)	Dementia	NH	 12-month NPS Incidence Rates 47.3% Any symptom 18.5% Agitation 22.7% Irritability 13.3% Aberrant motor behavior 4-year Cumulative Incidence Rates 36.0% Agitation 51.7% Irritability 41.2% Aberrant motor behavior
Wetzels <i>et al.</i> $(2010a)$	Netherlands	Longitudinal	2 years (specific years NR)	117	81.7 (7.4)	Dementia	NH	Incidence Rate (2-year range) (10.9%–18.2%)
Selbaek <i>et al.</i> (2008)	Norway	Cohort	1 year 2004/2005–2005/2006	923	NR	Dementia	NH	12-month NPS Incidence Rates43.8% Any symptom18.8% Agitation23.0% Irritability13.8% Aberrant motor behavior

Abbreviations: NH = nursing home; NPS = neuropsychiatric symptoms; NR = not reported.

REGION OR COUNTRY	PREVALENCE OF AGITATION	NUMBER O STUDIES	NUMBER OF SAMPLE SIZE STUDIES RANGE		MEAN AGE RANGE	
Agitation Preval	ence					
North America	5%-86%	11	126-5,092		74–85	
Europe	15%-88%	30	56-7	,580	60-85	
Asia	23%-63%	11	-		71-81	
Australia	23.10%	1	514	514 78		
Latin America	60.8%	1	1 217		78	
Africa	38.5%	1	78		85	
	N REPORTING					
	CHANGE IN NPS/		STUI	DY		
REGION OR	AGITATION	NUMBER O	F DURAT	FION S	SAMPLE SIZE	MEAN AGE
COUNTRY	OVER TIME	STUDIES	RAN	GE	RANGE	RANGE
Natural Progress	sion of Agitation					
Severity of agitatic	on					
U.S.*	2	4	18 mor 6 yea		78–462	74–82
Europe*	4	5	1-6 ye		56-330	74–84
China	1	1	2 yea		56	60
Australia	1	1	3 yea	ars	514	78
Prevalence of agita	ation		c c			
U.S.*	0	2	3–14 y	vears	323-497	74-85
Europe*	3	6	2–14 y		117–7,580	74–84
	N REPORTING					
	ASSOCIATION OF	TOTAL				MEAN
REGION OR	AD SEVERITY AND	NUMBER	SAMPLE	% AD		AGE
COUNTRY	AGITATION/NPS	OF STUDIES	SIZE RANGE	PATIEN	τ % demen	TIA RANGE
	AD Severity with Agitat	ion				
North America	8	9	78–5,092 2		44%	5 74–86
Europe	10	13	65–1,015	38%	38%	60-85
Asia	5	8	34–921	63%	13%	
South America	1	2	156-217	100%	0	77–78
Australia	1	1	514	0	100	78
Africa	1	1	108	0	100	73

* One study U.S./Europe.

Abbreviations: AD = Alzheimer's disease; NPS = neuropsychiatric symptoms; U.S. = United States.

Twenty-three of the 55 studies (42%) reported prevalence of at least one neuropsychological symptom and reported a range of 40% to 100%. Community-dwelling or outpatient clinic participants were the primary population studied in 26 (47%) studies; NH or group home residents were the primary population in 16 (29%) studies; a combination of NH and community-dwelling participants were the primary population in five (9%) studies; hospital patients were the primary population in five (9%) studies, and three (5%) studies did not report the source of their primary population. Most studies screened participants only for AD (n=28) or dementia (n=25), while a couple screened for memory loss/cognitive impairment (n=2).

Prevalence variations by geographical region

Europe

Participants specifically included in the 30 studies (55%) that originated from Europe included participants with AD (n = 14) and dementia (n = 15); one study recruited for cognitive impairment, looking at NPS prevalence rates (Gustafsson *et al.*, 2013). Of these 30 studies, 15 were cross-sectional (including one retrospective cross-sectional study) and 15 were longitudinal. The range of prevalence of agitation was reported to be 24 % to 88 %, with 14 studies (47%) showing an agitation prevalence rate $\geq 50\%$. Sixteen studies (53%) reported prevalence rates of at least one NPS, which ranged from 49.6% to 96.1%. Prevalence rates for agitation in European




Figure 2. Prevalence of agitation by geographic region. Abbreviation: U.S. = United States.

studies ranged from 24% to 88% for NH or geriatric facility participants (n = 13); 18.6% to 76% for community-dwelling participants (n = 13); 34.1% to 75.4% for NH plus community-dwelling participants (n = 2); and one study reported a prevalence rate for hospital participants of 44.8% (D'Onofrio *et al.*, 2012).

Asia

Participants in the 11 studies (20%) that originated from Asia included participants with AD (n = 7) and dementia (n = 4). The range of prevalence of agitation was reported as 23.3% to 78% in 10 studies, with two (17%) showing an agitation prevalence rate $\geq 50\%$. Four studies (33%) reported prevalence rates of at least one NPS, which ranged from 74.9% to 100%. Prevalence rates for agitation ranged from 23.3% to 63.1% for community-dwelling or outpatient participants (n = 7); 16.2% to 52.2% for NH plus community-dwelling participants (n = 3); and one study reported a prevalence rate for hospital participants of 52% for women and 78% for men (Kitamura *et al.*, 2012).

NORTH AMERICA

Participants in the 11 studies (20%) that originated from North America (nine in the United States [U.S.]) included participants with AD (n=4), dementia (n=4), the general geriatric population (n=2), and participants with memory loss (n=1). The range of prevalence of agitation was reported as 5% to 86% in 10 studies, with four (36%) showing an agitation prevalence rate \geq 50%. Two studies (18%) reported prevalence rates of at least one NPS, which ranged from 50.9% to 89%. Prevalence rates for agitation ranged from: 6.9% to 86% for community-dwelling participants (n=5), 50.4% for NH participants (n=1), and 31% for NH plus community-dwelling participants (n = 1) (Orengo *et al.*, 2008); three studies that did not report the source of their study sample reported a prevalence rate ranging from 5.3% to 40%.

OTHER COUNTRIES

Participants in the three studies (5%) that originated from other countries (Australia, Tanzania, and Brazil) included participants with AD (n = 1) and dementia (n = 2). The range of reported prevalence of agitation/aggressiveness was 15.3% to 60.8%, with one study (33%) showing an agitation prevalence rate \geq 50%. Two studies (67%) reported prevalence rates of at least one NPS, which ranged from 88.4% to 98%.

Natural progression of agitation/behavioral symptoms in AD

Seventeen studies that evaluated disease progression of agitation/behavioral symptoms in AD were identified. Studies presenting results on changes in severity of NPS or changes in prevalence rates over time were reviewed.

Of the 10 papers that evaluated changes in severity/frequency of agitation/NPS over time, six reported an increase (Brodaty *et al.*, 2015; Pan *et al.*, 2013; Selbaek *et al.*, 2008; Trzepacz *et al.*, 2013; Vogel *et al.*, 2015; Zahodne *et al.*, 2015); one reported a decrease (Wolf-Ostermann *et al.*, 2012); and one reported no change (Bergh *et al.*, 2011). Two studies had mixed results. Burgio and colleagues (2007) reported little change in agitation over an 18-month period according to staff report; while direct observation showed a statistically significant (*P* value <0.05) trajectory of agitation with decreasing trend. In the study conducted by Fauth and colleagues (2006), using a mixed-model analyses, group-level analysis showed no change, while intra-individual results suggested an increase in prevalence of disruptive behavior. Evaluated timeframes ranged from 24 weeks to 6 years. The evidence suggests there is an increase in severity of agitation symptoms over time, although some studies provided mixed results.

Of the nine papers evaluating changes in prevalence of agitation/NPS over time, six reported an increase (Gonfrier *et al.*, 2012; Lustenberger *et al.*, 2011; Scarmeas *et al.*, 2007; Selbaek *et al.*, 2008, 2014; Wetzels *et al.*, 2010b); two reported no or little change (Bergh *et al.*, 2011; Mitchell *et al.*, 2009); and none reported a decrease. Of note, agitation persisted at most timepoints over 4 years in the study by Hendriks and colleagues (2015) but decreased in the last week of life. Evaluated timeframes ranged from 1 to 14 years. The evidence suggests agitation/ NPS becomes more prevalent over time.

The most common clinical outcome assessment (COA) used in the studies was the Neuropsychiatric Inventory (NPI). Of the studies that evaluated the change in overall NPS over time (n = 14), 11 used the NPI as the primary endpoint measure. Other measures used included the Cohen-Mansfield Agitation Inventory (CMAI), the Disruptive Behavioral Symptoms measure (DBS), nurse or staff reports, direct observation, and the Columbia University Scale for Psychopathology in AD (CUSPAD). This variation in assessment methods can contribute to the variations in reported results.

Variations in natural progression by geographical region

Nearly half of the studies on natural progression were completed in Europe (n = 9/17); four studies were completed in the United States, one in Asia, and one in Australia, and two were a combined effort between Europe and the U.S. A greater percentage of European studies used a population sample of NH residents than U.S. studies (78% vs. 50%), and a greater percentage of U.S. studies used a population sample of community-dwelling residents than European studies (50% vs. 22%); the Asian study used a hospital population (Pan *et al.*, 2013) and the Australian study used a communitydwelling population (Brodaty *et al.*, 2015).

There were noteworthy differences in results of the course of agitation over time between the United States and Europe. More European studies showed an increase in agitation prevalence over time than U.S. studies (67% vs. 25%), and more U.S. studies showed little or no change in prevalence or frequency over time than European studies (50% vs. 11%). One European study indicated no change in agitation severity (Bergh *et al.*, 2011), and one study showed mixed results—the NPI total score decreased over time but all domains of the CMAI showed an increase in agitation over time (Wolf-Ostermann *et al.*, 2012). Of the combined U.S./ European studies, mixed results were reported; one showed an increase in disruptive behavioral symptoms over time (Scarmeas *et al.*, 2007), and the other demonstrated that the prevalence of agitation worsened over time, but was not significant when adjusting for cognitive decline (Zahodne *et al.*, 2015). Both the Asian and Australian studies showed an overall increase in NPS severity (Brodaty *et al.*, 2015; Pan *et al.*, 2013), although only one found increases in agitation outcomes specifically. (Brodaty *et al.*, 2015)

Disease severity and agitation/behavioral symptoms in AD

Thirty-four studies assessed some association between AD severity and NPS/agitation. Of these, 25 (74%) established an association between NPS or agitation and disease severity, four (12%) established a trend towards an association between the two without establishing statistical significance or testing for it, one study (3%) reported mixed results, and four studies (12%) reported no association between agitation/NPS and AD.

Results were examined separately for studies that explicitly noted assessment of agitation and those that assessed related NPS, but did not focus explicitly on agitation. Of the 34 studies that investigated the relationship between disease severity and NPS, 25 (74%) evaluated the relationship between agitation and disease severity, nine studies (26%) evaluated the relationship between NPS and disease severity, and six studies (18%) evaluated both agitation and overall NPS by disease severity.

Of the 25 studies that evaluated the relationship between agitation and disease severity, 17 (68%) demonstrated a significant association between the two, four studies (16%) showed a trending association (de Oliveira *et al.*, 2015; Ismail *et al.*, 2007; Karttunen *et al.*, 2011; Park *et al.*, 2015), and four studies (Fernandez-Martinez *et al.*, 2010; Kim and Lee, 2014; Pinidbunjerdkool *et al.*, 2014; Treiber *et al.*, 2008) (16%) demonstrated that there was no significant relationship between agitation and disease severity.

Of the 17 studies that showed a significant relationship between agitation and disease severity, 11 (65%) were cross-sectional and six (35%) were longitudinal. Dementia severity in these 17 studies was evaluated by the Mini-Mental State Examination (MMSE) (n=4) (Burgio *et al.*, 2007; Hamuro *et al.*, 2007; Kasai *et al.*, 2015; O'Donnell *et al.*, 2007), the Global Deterioration Scale (GDS) (n=2) (Mulders *et al.*, 2016; Steinberg *et al.*, 2006), the

Clinical Dementia Rating Scale (CDR; n=4) (Helvik *et al.*, 2016; Liu *et al.*, 2007; Selbaek *et al.*, 2014; Tanaka *et al.*, 2015), both the MMSE and CDR (n=2) (D'Onofrio *et al.*, 2012; Peters *et al.*, 2015), or studies did not specify (n=5). Of these 17 studies showing significant results, agitation was reported as being measured by the NPI in four studies (Fernandez Martinez *et al.*, 2008; Helvik *et al.*, 2016; Peters *et al.*, 2015; Tanaka *et al.*, 2016; Steinberg *et al.*, 2008), and Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) in one (Liu *et al.*, 2007). Other studies either did not specify or used a study-unique definition of agitation (n=10).

Of the 11 cross-sectional studies (n = 11/17) that reported a significant relationship between agitation and disease severity, three used the CDR to define dementia severity and one study showed agitation to be significantly predictive of the severity of cognitive impairment (moderate-severe dementia: CDR = 2-3 and MMSE score <18) in AD patients (D'Onofrio et al., 2012). A second study, by Helvik and colleagues (2016), showed that some CDR groups (defined as CDR <1: none; CDR = 1: mild; CDR = 2: moderate, CDR = 3: severe) were significantly associated with agitation. Tanaka and colleagues (2015) compared NPI agitation scores by CDR groups (mild, moderate, and severe classifications); the association was significant between agitation and all CDR groups (P value < 0.001).

Six longitudinal studies demonstrated significant association between agitation and disease severity. One study reported disease severity using CDR scores (Selbaek et al., 2014), showing that CDR scores of 2 (P value = 0.02) or 3 (P value < 0.001) were significantly predictive of agitation. Another study compared GDS groups (defined as 1, 2, 3, 4, 5, 6, and 7) against CMAI subdomains, demonstrating that agitation was significantly predictive of dementia severity in all CMAI subdomains (Steinberg et al., 2008). A third study, by Morgan and colleagues (2013), communicated a significant association between agitation and dementia severity (r = -0.19, P value < 0.001). Another study compared AD groups by mild, moderate, and severe AD, demonstrating that mild vs. moderate AD groups showed significantly significant differences in agitation levels (P value = 0.045) (Pink *et al.*, 2015). A study by Peters and colleagues (2015) demonstrated that agitation was significantly predictive of progression to severe dementia (hazard ratio: 2.946, P value = 0.004). Severe dementia was measured using the MMSE and CDR; severe AD was defined as an MMSE score of ≤ 10 or CDR score = 3. The sixth study reported that the severity of dementia increased the odds of agitation (odds ratio: 2.42, confidence interval: 1.81–3.23, *P* value <0.01) (Steinberg *et al.*, 2006).

Papers investigating the association between AD severity and other NPS

Nine studies (n = 9/34) evaluated the relationship between NPS and disease severity, either using a total score for NPS or by evaluating the relationship by NPS type. Additionally, five studies that evaluated the relationship between agitation and disease severity also included results on other NPS, for a total of 14 studies. Of these 14 studies, 10 (Amoo et al., 2011; Brodaty et al., 2015; Conde-Sala et al., 2016; D'Onofrio et al., 2012; 2016; Karttunen et al., 2011; Khoo et al., 2013; Koppitz et al., 2015; Spalletta et al., 2010; Stella et al., 2016) demonstrated a statistically significant relationship between NPS and disease severity. Four (de Oliveira et al., 2015; Ismail et al., 2007; Karttunen et al., 2011; Park et al., 2015) did not. Eight of the 10 statistically significant studies demonstrated significant associations between the degree of dementia severity and NPS, measured by total NPS score (Brodaty et al., 2015; Conde-Sala et al., 2016; D'Onofrio et al., 2012; Karttunen et al., 2011; Khoo et al., 2013; Koppitz et al., 2015; Spalletta et al., 2010; Stella et al., 2016). One study showed a significant relationship between specific NPS type and disease severity, including disinhibition and aberrant motor behavior (Amoo et al., 2011); another study, measuring both general and specific NPS, found a significant relationship between specific NPS type and disease severity, including irritability/lability and aberrant motor activity (D'Onofrio et al., 2016).

Regional differences in associations of disease severity with agitation

Most studies evaluating the relationship between agitation/NPS and disease severity originated from Europe (n=13/34); followed by North America (n=9/34), Asia (n=8/34), South America (n=2/34), Africa (n=1/34), and Australia (n=1/34). Noteworthy regional differences included differences in population sample by region and residence of study population by region.

Studies originating in South America and Africa had the most studies that identified AD patients as their study population (100%), followed by Asia (63%, n=5; Dementia = 12%, n=1; Mixed = 25%, n=2), Europe (38%, n=5; Dementia = 38%, n=5; Mixed = 23%, n=3), and North America (22%, n=2; Dementia = 44%, n=5; Memory loss = 22%, n=2).

The most common place of residence from which participants were drawn was communitydwelling residents, and the highest sample draw of community-dwelling residents came from South American studies (100%, n = 2), followed by Asian (63%, n = 5), North American (63%, n = 5), and European (46%, n = 6). NH resident study populations were more common in European (46%, n = 6) and North American studies (25%, n = 2) than Asian (22%, n = 2) or South American (0%, n = 0).

Significant findings associated with agitation/ NPS and disease severity were found more often in studies originating in North America (89%, n=8), followed by Europe (77%, n=10), Asia (63%, n=5), and South America (50%, n=1). The single studies from Australia and Africa also reported significant association. Non-significant findings of this association were most common in Asia (22%, n=2; trending findings 11%, n=1), followed by European studies (8%, n=1; trending findings 8%, n=1). Two regions had no nonsignificant results, but had one study each with trending findings (South America n=1, 50%; North America n=1, 11%).

Mortality associated with agitation in AD

There were five studies that provided information on the association between agitation and mortality, and issues around death, which were included in the review (Table 4). The studies were from different settings, including nursing homes (n = 2), an outpatient clinic (n = 1), and mixed settings (n = 1); one setting was not reported.

Most studies provided estimates of association of agitation with mortality (n=3). Two studies (Peters and colleagues, 2015; Sampson and colleagues, 2015) reported a significant association of agitation-related symptoms and mortality. Peters and colleagues (2015) reported results of a longitudinal population-based study, using data from 1995–2009, and reported that agitation is a significant predictor of death, controlling for age of dementia onset, gender, education level, general health rating, and apolipoprotein E epsilon 4 (APOE- ε 4) genotype status. Results of a longitudinal cohort study of people with dementia admitted to an acute care hospital also reported significant association between severity of NPS and mortality. (Sampson et al., 2015) In a retrospective cohort study with NH AD patients, while reduction in behavioral symptoms as a result of treatment was associated with reduced risk of mortality, this association did not reach statistical significance. (Huang et al., 2015)

The study by Koyama and colleagues (2015) did not directly assess the association between mortality and agitation in dementia patients. Instead, it provided information on the relationship between suicidal ideation of dementia patients and NPS. Ten percent of the dementia patients in the sample had suicidal thoughts. NPI-Agitation/Aggression (NPI-A/A) scores were statistically different for patients with and without suicidal thoughts (P value = 0.004)

The Vandervoort and colleagues (2013) study investigated palliative quality of life in dementia patients. Patients that were included in this research were patients that had died in the previous 3 months. In the last month of life, pain, fear, anxiety, resistance to care, and agitation were the most frequently reported symptoms of dementia.

A few studies directly examined the association between agitation in dementia and mortality risk, and provided some evidence supporting a positive relationship. However, there is minimal research in this area. Further research exploring the relationship between dementia agitation and risk of death, and providing an understanding of the interaction of that relationship, would be beneficial.

Discussion

In this systematic review, a wide range of agitation prevalence rates were reported (5% to 88%), with rates varying somewhat by geographic region (lower ranges were reported for Asia). Most studies, however, reported prevalence rates that were under 50%. Few estimates were based on large samples. The years for which estimates were provided varied, patients from both outpatient and clinical settings were used, and many agitation assessments were used. These variations in study design make it difficult to provide a reliable estimate on the true prevalence rate of agitation symptoms in AD patients.

Seventeen studies reported on the natural progression of agitation/NPS in AD. Results suggested agitation severity ratings increase over time, while the proportion of patients with symptoms increase slightly or remain stable over time. While some geographic variations were detected in prevalence rates and the course of agitation and associations reported between AD severity and agitation, the heterogeneity of the included studies on multiple dimensions suggests that such differences should be examined tentatively and with caution.

The relationship between AD severity and agitation was evaluated in a substantial number of studies and was supported by most of them, providing one of the most robust findings of the review.

Overall, this review was broad in scope, and the results on agitation prevalence align with findings from earlier reviews that focused on prevalence and progression of NPS in patients with AD and/or dementia. Borsje and colleagues (2015) conducted a systematic review of studies reporting the course of NPS in community-dwelling adults with dementia,

Table 4. Studies on agitation and mortality

CITATION	COUNTRY	TYPE OF STUDY	TIME PERIOD	SAMPLE SIZE	AGE	STUDY Population	SETTING	SURVIVAL/RISK OF DEATH
Huang <i>et al.</i> (2015)	US	Retrospective Longitudinal	Running baseline/ reassessment 2006–2009	3,696	83.2 (9.8) Anti-psychotic 82.3 (10.6) Anti-depressant	Dementia	NH	Patients on APs whose symptoms improved less likely to die with 6 months, but effect NS: LR 6-month mortality OR (95% CI) = 0.89 (0.70–1.13); Cox mortality HR (adjusted) (95% CI) = 0.93 (0.81–1.07)
Peters <i>et al.</i> (2015)	US	Longitudinal	1995–2009	5,092 (335 AD cases)	84.3 (6.4)	Population sample	NR	Earlier death related to affective and mild NPS (HR = 1.951, p = <0.001)
Vandervoort et al. (2013)	Belgium	Post-mortem	2010	198	86.7 age at death (SD NR)	Dementia	NH	Agitation among the top 3 distressing symptoms during the last months of life.
Koyama <i>et al.</i> (2015)	Japan	Cross-sectional	2007–2013	634	77.3 (SD NR)	Dementia and AD	Outpatient	10.1% prevalence of suicidal ideation NPI-A/A statistically different for patients with and without ideation ($p = 0.004$)
Sampson et al. (2014)	UK	Longitudinal cohort	2011–2012	230	87.2 (5.9)	Dementia	Mixed	Severity of BEHAVE-AD aggression as predictor of mortality: OR 1.23; 95% CI 1.06–1.44; p=0.008

Abbreviations: AD = Alzheimer's disease; AP = antipsychotic; BEHAVE-AD = Behavioral Pathology in Alzheimer's Disease Rating Scale; <math>CI = confidence interval; HR = hazard ratio; LR = last-reported; NH = nursing home; NPI-A/A = Neuropsychiatric Inventory-Agitation/Aggression domain NPS = neuropsychiatric symptoms; <math>NR = not reported; NS = not significant; OR = odds ratio; SD = standard deviation; UK = United Kingdom; US = United States.

including 23 studies in the data synthesis. Overall, the authors concluded that NPS are highly prevalent and persistent, but frequency parameters varied considerably across studies. Data on agitation was provided by nine of the included studies, and agitation was noted as one of the symptoms, with high prevalence an increasing trend over time. Reported point prevalence rates for wandering or agitation were 18% to 62%, while cumulative prevalence rate ranged between 40% to 100%. These wide ranges are consistent with the findings from our review. Another point of consistency for our review is the large number of NPS measures used for assessment of NPS, which was also noted in a review by Wetzels and colleagues (2010a); this review identified 12 measures used across 18 publications.

A separate review examined the prevalence and course of NPS in patients with dementia, including population-based studies, outpatient, and long-term patient populations (Bergh and Selbæk, 2012). Only studies using the NPI were reviewed; prevalence rates were examined for persons with dementia included in population-based studies, attending outpatient clinics, or living in long-term care facilities. Agitation was among the symptoms with the highest prevalence rates reported—a median of 27% for population-based studies and long-term care patients, and 37% for outpatients. The course of agitation was persistent for outpatient populations, while resolution rates were reported for long-term facilities. On the other hand, Wetzels and colleagues (2010a) reported increasing trends for agitation, suggesting that population setting may be an important variable to consider when the course of agitation is examined.

Van Der Linde and colleagues (2012) conducted a systematic review to give a broad overview of the prevalence, course, biological and psychosocial associations, care, and outcomes of behavioral and psychological symptoms in an older population with dementia. The authors examined 36 reviews, but none focused specifically on agitation in AD. Agitation was noted as one of the most prevalent symptoms identified by reviews in people with dementia. Consistent with our results, the authors noted that behavioral and psychological prevalence vary widely across reviews, but no specifics on agitation prevalence rates were provided.

Findings from our review are aligned with previously reported findings on agitation prevalence and natural progression. This review concluded that information is particularly scarce in areas including incidence rates of agitation and studies specifically examining the relationship between agitation symptoms and mortality. No U.S. study on incidence rates was identified. A possible reason for the low number of studies on incidence of agitation is the challenge of defining, measuring, and differentiating agitation incidence versus agitation prevalence for a symptom that is not constantly present. Finally, information from studies conducted with community-dwelling patients is relatively scarce.

The results of this systematic review suggest a need to clearly establish a unified understanding of the commonalities surrounding agitation in the context of AD, which should be built on a foundation of quality standardized methodology. Only by clearly understanding the incidence of agitation and its burden on AD patients can the medical community help identify the most appropriate treatment.

The key findings of this study need to be considered in the context of its limitations and study design. This systematic review was conceptualized as a broad review of information related to agitation burden for AD, and all study designs were accepted. In addition, a definition of agitation consistent with the IPA definition was used, including specific behaviors and related NPS; this could have possibly introduced some noise in the key findings as there is variability in how agitation is defined and measured in the literature. The target population was also broadly defined as patients with AD or dementia. These factors may contribute to the wide variability of papers included in the systematic review and lead to challenges in consistently summarizing and interpreting all information, in addition to bringing inherent variability in results.

This review summarized available evidence on incidence, prevalence, and course of agitation, as well as studies on the association of agitation with AD severity and mortality. Consistent with earlier reports, agitation is highly prevalent, but the course of the symptoms over time seems to depend on multiple factors. Evidence for the association of agitation with AD appears to be strong, as most studies identified reported significant association despite heterogeneity in measures and designs used. There is limited information on the specific association of agitation symptoms and mortality; lack of existing evidence suggests additional studies to better understand possible associations is warranted.

Conflict of interest

Ruth A. Duffy, Ross A. Baker, and Myrlene Sanon Aigbogun are employed by Otsuka Pharmaceutical Development and Commercialization, Inc. Ann Hartry and Lene Hammer-Helmich are employed by Lundbeck LLC. Milena Anatchkova, Anne Brooks, and Laura Swett are employed by Evidera, which provides consulting and other research services to pharmaceutical, medical device, and related organizations. In their salaried positions, they work with a variety of companies and organizations, and are precluded from receiving payment or honoraria directly from these organizations for services rendered. Evidera received funding from Otsuka and Lundbeck to participate in the study and the development of this manuscript.

All authors participated in study design, data analysis and interpretation, and contributed to the development of the manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work, and have given final approval to the version to be published.

Description of authors' roles

M. Anatchkova participated in the study design, supervised data collection and analyses, and drafted the paper. L. Swett and A. Brooks supervised data collection, conducted data analysis, and prepared tables for the manuscript. M. Sanon Aigbogun and A. Hartry participated in the study design, protocol review, review of analyses, interpretation of findings, and review of the manuscript. R. Duffy, R. Baker, and L. Hammer-Helmich participated in the protocol review, review of analyses, interpretation of findings, and review of the manuscript.

Acknowledgments

The authors thank Michael Grossi of the Evidera Editorial and Design Services team for his assistance in editing and preparing the manuscript for submission.

Supplementary material

To view supplementary material for this article, please visit https://doi.org/10.1017/S104161021800 1898.

References

- Alzheimer's Association (2015). 2015 Alzheimer's disease facts and figures. Alzheimer's & Dementia, 11, 332–384.
- Alzheimer's Society (2011). Optimising Treatment and Care for People with Behavioural and Psychological Symptoms of Dementia. A Best Practice Guide for Health and Social Care Professionals. London: Alzheimer's Society.
- Amoo, G. et al. (2011). Profile of clinically-diagnosed dementias in a neuropsychiatric practice in Abeokuta, south-western Nigeria. African Journal of Psychiatry, 14, 377–382. doi: 10.4314/ajpsy.v14i5.5.

- Anatchkova, M. et al. (2017). The economic burden of agitation in Alzheimer's disease: a systematic literature review. Presented at ISPOR 22nd Annual International Meeting, May 20–24, Boston, MA.
- Bergh, S., Engedal, K., Roen, I. and Selbaek, G. (2011). The course of neuropsychiatric symptoms in patients with dementia in Norwegian nursing homes. *International Psychogeriatrics*, 23, 1231–1239. doi: 10.1017/ S1041610211001177.
- Bergh, S. and Selbæk, G. (2012). The prevalence and the course of neuropsychiatric symptoms in patients with dementia. *Norsk Epidemiologi*, 22, 225–232. doi: 10.5324/ nje.v22i2.1570.
- Borsje, P., Wetzels, R. B., Lucassen, P. L., Pot, A. M. and Koopmans, R. T. (2015). The course of neuropsychiatric symptoms in community-dwelling patients with dementia: a systematic review. *International Psychogeriatrics*, 27, 385–405. doi: 10.1017/S1041610214002282.
- Brodaty, H., Connors, M. H., Xu, J., Woodward, M., Ames, D. and PRIME Study Group (2015). The course of neuropsychiatric symptoms in dementia: a 3-year longitudinal study. *Journal of the American Medical Directors Association*, 16, 380–387. doi: 10.1016/j.jamda .2014.12.018.
- Burgio, L. D., Park, N. S., Hardin, J. M. and Sun, F. (2007). A longitudinal examination of agitation and resident characteristics in the nursing home. *The Gerontologist*, 47, 642–649. doi: 10.1093/geront/47.5.642.
- Conde-Sala, J. L. et al. (2016). Effects of anosognosia and neuropsychiatric symptoms on the quality of life of patients with Alzheimer's disease: a 24-month follow-up study. *International Journal of Geriatric Psychiatry*, 31, 109–119. doi: 10.1002/gps.4298.
- Cummings, J. et al. (2015). Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. *International Psychogeriatrics*, 27, 7–17. doi: 10.1017/S1041610214001963.
- D'Onofrio, G. et al. (2012). Neuropsychiatric symptoms and functional status in Alzheimer's disease and vascular dementia patients. *Current Alzheimer Research*, 9, 759–771. doi: 10.2174/156720512801322582.
- **D'Onofrio, G.** et al. (2016). Delusions in patients with Alzheimer's disease: a multidimensional approach. *Journal* of Alzheimer's Disease, 51, 427–437. doi: 10.3233/JAD-150944.
- de Oliveira, F. F., Wajman, J. R., Bertolucci, P. H., Chen, E. S. and Smith, M. C. (2015). Correlations among cognitive and behavioural assessments in patients with dementia due to Alzheimer's disease. *Clinical Neurology and Neurosurgery*, 135, 27–33. doi: 10.1016/j.clineuro .2015.05.010.
- Fauth, E. B., Zarit, S. H., Femia, E. E., Hofer, S. M. and Stephens, M. A. (2006). Behavioral and psychological symptoms of dementia and caregivers' stress appraisals: intra-individual stability and change over short-term observations. *Aging and Mental Health*, 10, 563–573. doi: 10.1080/13607860600638107.
- Fernandez-Martinez, M., Molano, A., Castro, J. and Zarranz, J. J. (2010). Prevalence of neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease, and its relationship with cognitive impairment. *Current Alzheimer Research*, 7, 517–526.

Fernandez Martinez, M., Flores, J. C., De Las Heras, S. P., Lekumberri, A. M., Menocal, M. G. and Imirizaldu, J. J. Z. (2008). Prevalence of neuropsychiatric symptoms in elderly patients with dementia in Mungialde County (Basque Country, Spain). *Dementia and Geriatric Cognitive Disorders*, 25, 103–108. doi: 10.1159/000112215.

Gonfrier, S., Andrieu, S., Renaud, D., Vellas, B. and Robert, P. H. (2012). Course of neuropsychiatric symptoms during a 4-year follow up in the REAL-FR cohort. *The Journal of Nutrition, Health and Aging*, 16, 134–137.

Gustafsson, M., Sandman, P. O., Karlsson, S., Gustafson, Y. and Lovheim, H. (2013). Association between behavioral and psychological symptoms and psychotropic drug use among old people with cognitive impairment living in geriatric care settings. *International Psychogeriatrics*, 25, 1415–1423. doi: 10.1017/ S1041610213000859.

Hamuro, A. *et al.* (2007). Behavioral and psychological symptoms of dementia in untreated Alzheimer's disease patients. *Psychogeriatrics*, 7, 4–7. doi: 10.1111/j.1479-8301 .2006.00153.x.

Helvik, A. S. et al. (2016). Severity of neuropsychiatric symptoms in nursing home residents. *Dementia and Geriatric Cognitive Disorders Extra*, 6, 28–42. doi: 10.1159/ 000442250.

Hendriks, S. A., Smalbrugge, M., Galindo-Garre, F., Hertogh, C. M. and van der Steen, J. T. (2015). From admission to death: prevalence and course of pain, agitation, and shortness of breath, and treatment of these symptoms in nursing home residents with dementia. *Journal of the American Medical Directors Association*, 16, 475–481. doi: 10.1016/j.jamda.2014.12.016.

Huang, T. Y., Wei, Y. J., Moyo, P., Harris, I., Lucas, J. A. and Simoni-Wastila, L. (2015). Treated behavioral symptoms and mortality in medicare beneficiaries in nursing homes with Alzheimer's disease and related dementias. *Journal of the American Geriatrics Society*, 63, 1757–1765. doi: 10.1111/jgs.13606.

Ismail, M. S., Dagerman, K., Tariot, P. N., Abbott, S., Kavanagh, S. and Schneider, L. S. (2007). National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics. *Current Alzheimer Research*, 4, 325–335.

Karttunen, K. et al. (2011). Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease. International Journal of Geriatric Psychiatry, 26, 473–482. doi: 10.1002/gps.2550.

Kasai, M., Meguro, K., Akanuma, K. and Yamaguchi, S. (2015). Alzheimer's disease patients institutionalized in group homes run by long-term care insurance exhibit fewer symptoms of behavioural problems as evaluated by the Behavioural Pathology in Alzheimer's Disease Rating Scale. *Psychogeriatrics*, 15, 102–108.

Khoo, S. A., Chen, T. Y., Ang, Y. H. and Yap, P. (2013). The impact of neuropsychiatric symptoms on caregiver distress and quality of life in persons with dementia in an Asian tertiary hospital memory clinic. *International Psychogeriatrics*, 25, 1991–1999. doi: 10.1017/ \$1041610213001518. Kim, H. and Lee, K. J. (2014). Serum homocysteine levels are correlated with behavioral and psychological symptoms of Alzheimer's disease. *Neuropsychiatric Disease and Treatment*, 10, 1887–1896. doi: 10.2147/NDT.S68980.

Kitamura, T., Kitamura, M., Hino, S., Tanaka, N. and Kurata, K. (2012). Gender differences in clinical manifestations and outcomes among hospitalized patients with behavioral and psychological symptoms of dementia. *Journal of Clinical Psychiatry*, 73, 1548–1554. doi: 10.4088/ JCP.11m07614.

Koppitz, A., Bosshard, G., Schuster, D. H., Hediger, H. and Imhof, L. (2015). Type and course of symptoms demonstrated in the terminal and dying phases by people with dementia in nursing homes. *Zeitschrift Für Gerontologie* und Geriatrie, 48, 176–183. doi: 10.1007/s00391-014-0668-z.

Koyama, A., Fujise, N., Matsushita, M., Ishikawa, T., Hashimoto, M. and Ikeda, M. (2015). Suicidal ideation and related factors among dementia patients. *Journal of Affective Disorders*, 178, 66–70. doi: 10.1016/j.jad.2015.02 .019.

Liu, C. Y., Wang, P. N., Lin, K. N. and Liu, H. C. (2007). Behavioral and psychological symptoms in Taiwanese patients with Alzheimer's disease. *International Psychogeriatrics*, 19, 605–613. doi: 10.1017/ S1041610207005121.

Lustenberger, I., Schupbach, B., von Gunten, A. and Mosimann, U. (2011). Psychotropic medication use in Swiss nursing homes. *Swiss Med Wkly*, 141, w13254. doi: 10.4414/smw.2011.13254.

Mitchell, S. L. et al. (2009). The clinical course of advanced dementia. New England Journal of Medicine, 361, 1529–1538. doi: 10.1056/NEJMoa0902234.

Morgan, R. O., Sail, K. R., Snow, A. L., Davila, J. A., Fouladi, N. N. and Kunik, M. E. (2013). Modeling causes of aggressive behavior in patients with dementia. *The Gerontologist*, 53, 738–747. doi: 10.1093/geront/gns129.

Mulders, A. J., Fick, I. W., Bor, H., Verhey, F. R., Zuidema, S. U. and Koopmans, R. T. (2016). Prevalence and correlates of neuropsychiatric symptoms in nursing home patients with young-onset dementia: the BEYOnD study. *Journal of the American Medical Directors Association*, 17, 495–500. doi: 10.1016/j.jamda.2016.01.002.

O'Donnell, M. J., Lewis, D. L., Dubois, S., Standish, T. I., Bédard, M. and Molloy, D. W. (2007). Behavioural and psychological symptoms in communitydwelling elderly persons with cognitive impairment and dementia: prevalence and factor analysis. *Clinical Gerontologist*, 30, 41–52.

Orengo, C. A. et al. (2008). Aggression in individuals newly diagnosed with dementia. American Journal of Alzheimer's Disease & Other Dementias, 23, 227–232. doi: 10.1177/ 1533317507313373.

Pan, W. D. et al. (2013). Quantitative evaluation of severity of behavioral and psychological symptoms of dementia in patients with vascular dementia. *Translational Neurodegeneration*, 2, 9. doi: 10.1186/2047-9158-2-9.

Park, H. K. et al. (2015). Cognitive profiles and neuropsychiatric symptoms in Korean early-onset Alzheimer's disease patients: a CREDOS study. *Journal of* Alzheimer's Disease, 44, 661–673. doi: 10.3233/JAD-141011. Peters, M. E. *et al.* (2015). Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study. *American Journal of Psychiatry*, 172, 460–465. doi: 10.1176/appi.ajp.2014.14040480.

Pinidbunjerdkool, A., Saengwanitch, S. and Sithinamsuwan, P. (2014). Behavioral and psychological symptoms of dementia. *Journal of the Medical Association of Thailand*, 97 Suppl 2, S168–S174.

Pink, A. et al. (2015). Neuropsychiatric symptoms, APOE epsilon4, and the risk of incident dementia: a populationbased study. *Neurology*, 84, 935–943. doi: 10.1212/WNL .000000000001307.

Porsteinsson, A. P. et al. (2014). Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. *JAMA*, 311, 682–691. doi: 10.1001/jama .2014.93.

Sampson, E. L. et al. (2014). Behavioural and psychiatric symptoms in people with dementia admitted to the acute hospital: prospective cohort study. *The British Journal of Psychiatry*, 205, 189–196. doi: 10.1192/bjp.bp.113 .130948.

Sampson, E. L. et al. (2015). Pain, agitation, and behavioural problems in people with dementia admitted to general hospital wards: a longitudinal cohort study. *Pain*, 156, 675–683. doi: 10.1097/j.pain.00000000 00000095.

Scarmeas, N. *et al.* (2007). Disruptive behavior as a predictor in Alzheimer disease. *Archives of Neurology*, 64, 1755–1761. doi: 10.1001/archneur.64.12.1755.

Selback, G., Engedal, K., Benth, J. S., Bergh, S. (2014). The course of neuropsychiatric symptoms in nursing-home patients with dementia over a 53-month follow-up period. *International Psychogeriatrics*, 26, 81–91. doi: 10.1017/ S1041610213001609.

Selbaek, G., Kirkevold, O. and Engedal, K. (2008). The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes–a 12-month follow-up study. *The American Journal of Geriatric Psychiatry*, 16, 528–536. doi: 10.1097/JGP.0b013e318167ae76.

Spalletta, G. et al. (2010). Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. *The American Journal of Geriatric Psychiatry*, 18, 1026–1035. doi: 10.1097/JGP .0b013e3181d6b68d.

Steinberg, M. et al. (2006). Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study. *International Journal of Geriatric Psychiatry*, 21, 824–830. doi: 10.1002/gps.1567.

Steinberg, M. et al. (2008). Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. International Journal of Geriatric Psychiatry, 23, 170–177. doi: 10.1002/gps.1858. Stella, F., Laks, J., Govone, J. S., de Medeiros, K. and Forlenza, O. V. (2016). Association of neuropsychiatric syndromes with global clinical deterioration in Alzheimer's disease patients. *International Psychogeriatrics*, 28, 779–786. doi: 10.1017/S1041610215002069.

Tanaka, H. et al. (2015). Relationship between dementia severity and behavioural and psychological symptoms in early-onset Alzheimer's disease. *Psychogeriatrics*, 15, 242–247. doi: 10.1111/psyg.12108.

Treiber, K. A. et al. (2008). Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study. International Psychogeriatrics, 20, 538–553. doi: 10.1017/S1041610208006704.

Trzepacz, P. T. *et al.* (2013). Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease. *Alzheimer's & Dementia*, 9, S95–S104 e1. doi: 10.1016/j.jalz.2012.10.005.

van der Linde, R. M., Stephan, B. C., Savva, G. M., Dening, T. and Brayne, C. (2012). Systematic reviews on behavioural and psychological symptoms in the older or demented population. *Alzheimer's Research & Therapy*, 4, 28. doi: 10.1186/alzrt131.

Vandervoort, A. et al. (2013). Nursing home residents dying with dementia in Flanders, Belgium: a nationwide postmortem study on clinical characteristics and quality of dying. *Journal of the American Medical Directors Association*, 14, 485–492. doi: 10.1016/j.jamda.2013.01.016.

Vogel, A., Waldorff, F. B. and Waldemar, G. (2015). Longitudinal changes in awareness over 36 months in patients with mild Alzheimer's disease. *International Psychogeriatrics*, 27, 95–102. doi: 10.1017/S10416102 14001562.

Wetzels, R. B., Zuidema, S. U., de Jonghe, J. F., Verhey, F. R. and Koopmans, R. T. (2010a). Course of neuropsychiatric symptoms in residents with dementia in nursing homes over 2-year period. *The American Journal of Geriatric Psychiatry*, 18, 1054–1065.

Wetzels, R. B., Zuidema, S. U., de Jonghe, J. F., Verhey, F. R. and Koopmans, R. T. (2010b). Determinants of quality of life in nursing home residents with dementia. *Dementia and Geriatric Cognitive Disorders*, 29, 189–197. doi: 10.1159/000280437.

Wolf-Ostermann, K., Worch, A., Fischer, T., Wulff, I. and Graske, J. (2012). Health outcomes and quality of life of residents of shared-housing arrangements compared to residents of special care units - results of the Berlin DeWeGE-study. *Journal of Clinical Nursing*, 21, 3047–3060. doi: 10.1111/j.1365-2702.2012.04305.x.

Zahodne, L. B., Ornstein, K., Cosentino, S., Devanand, D. P. and Stern, Y. (2015). Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation/aggression. *The American Journal of Geriatric Psychiatry*, 23, 130–140. doi: 10.1016/j. jagp.2013.03.014.